

Anagrelid zur Behandlung der primären Thrombozythämie

Pharmakologie und klinische Anwendung

Petro E. Petrides, München

Literatur

- Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. *Cancer Chemother Pharmacol* 2003;51:81–6.
- Anagrelide study group. Anagrelide, a therapy for thrombocytotic states: experience in 577 patients. *Am J Med* 1992;92:69–76.
- Anahydret-Studie. Information im Internet unter www.anahydret.at
- Andersson BS. Essential thrombocythemia: diagnosis and treatment with special emphasis on the use of anagrelide. *Hematology* 2002;7:173–7.
- Andes WA, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. *Thromb Hemostasis* 1984;52:325–8.
- AOP-Studie. Bioäquivalenzstudie, Data on File, AOP 01-007
- Balduini CL, Bertolino G, Noris P, Ascarì E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. *Haematologica* 1992;77:40–3.
- Barbui T, Finazzi G, Ruggeri M, Rodeghiero F. Secondary leukemia following hydroxyurea in patients with essential thrombocythemia: long term results of a randomized clinical trial. *Blood* 1998;92(Suppl 1):ASH abstract 2016.
- Bellucci S, Legrand C, Boval B, Drouet L, et al. Studies on platelet volume, chemistry and function in patients with essential thrombocythemia treated with anagrelide. *Br J Haematol* 1999;104:886–92.
- Bennett CL, Weinberg PO, Golub RM. Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? *Sem Hematol* 1999;36(Suppl 2):26–9.
- Bennett M, Grunwald AJ. Hydroxyurea and periodicity in myeloproliferative disease. *Eur J Hematol* 2001;66:317–23.
- Berger A, Arnold J, Dukstein W, et al. ¹¹¹In-dium labelled autologous platelet survival during aggregation inhibition by anagrelide in normal volunteers. *Clin Pharm Therap* 1983;33:219.
- Best PJM, Pettitt RM. Multiple skin cancers associated with hydroxyurea therapy. *Mayo Clin Proc* 1998;73:961–3.
- Beykirch MK, Trapp O, Petrides PE. Primäre Thrombozythämie. *Diagnose und Therapie. Arzneimitteltherapie* 1997;15:309–11.
- Beykirch MK, Trapp OM, Petrides PE. Neue Entwicklungen in der Behandlung primärer Thrombozytosen. *Acta Med Austriaca* 1998;25(Suppl 46):8.
- Birgegard G, Björkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. *Haematologica* 2004;89:520–7.
- Braester A, Laver B. Anagrelide-induced erectile dysfunction. *Ann Pharmacother* 2002;36:1291.
- Bravo Blanco AM, Moral JL, Tembras S, et al. Hydroxyurea induced skin ulcerations in patients with chronic myeloproliferative disorders. *J Hematother Stem Cell Res* 2003;12:461–3.
- Brooks WG, Stanley DD, Goode J. Role of anagrelide in the treatment of thrombocytosis. *Ann Pharmacother* 1999;33:1116–21.
- Burkhard H, Adam H, Widmer L, et al. Anagrelid zur Kontrolle der myeloproliferativen Thrombozythämie: Langzeiterfahrung bei 6 Patienten. *Schweiz Med Wochenschr* 1998;128:1808–12.
- Chintagumpala MM, Steuber CP, Mahoney DH, et al. Essential thrombocythemia in a child: management with anagrelide. *Am J Pediatr Hematol Oncol* 1991;13:52–6.
- Chintagumpala MM, Kenney LL, Steuber CP. Treatment of essential thrombocythemia with anagrelide. *J Pediatr* 1995;127:495–8.
- Clark WF, Reid BD, Tevaarwerk GJM. Anagrelide: inhibitor of collagen and immune complex induced platelet aggregation and release. *Thromb Res* 1981;21:215–9.
- Colton DG, Paige JB, Fleming JS, Buyniski JP. Effect of the antithrombotic agent anagrelide (AL) on thrombin-stimulated human platelet arachidonic acid (AA) metabolism. 66th Annual FASEB Meeting, New Orleans, 1982: abstract 7557.
- Cortelazzo S, et al. Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis. *New Engl J Med* 1995;332:1132–6.
- Courtwright WE, Buchanon JO, Fleming JS, Taylor R. The effect of multiple oral doses of anagrelide on ADP and collagen-induced platelet aggregation in normal male subjects. *Clin Pharmacol Ther* 1983;X:220.
- Drescher CW, Chucales AG, Grocock AM, Lucchesi BR. The effects of BL-4162A on the development of coronary artery thrombosis in the conscious rat. *Clin Res* 1979;27:716A.
- Dror Y, Blanchette VS. Essential thrombocythemia in children. *Br J Haematol* 1999;107:691–8.
- Erusalimski JD, Hong Y, Franklin R. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)? *Exp Hematol* 2002;30:625–6.
- Erusalimski JD, Wang G, Hong Y. The anagrelide metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603) is a poor inhibitor of in vitro megakaryopoiesis. *Blood* 2002;100:ASH abstract 4950.
- Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. *Blood* 2000;96:4261–6.
- FDA-Data, on file.
- Finazzi G, Ruggeri M, Redeghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized trial. *Br J Haematol* 2000;116:923–4.
- Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. *Blood* 2003;101:3749.
- Fleming JS, Buyniski JP. A new potent inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). *Thromb Res* 1979;15:373–88.
- Fruchtman SM, Pettitt RM, Gilbert HS, Fiddler G, et al. Anagrelide. Analysis of long term safety and leukemogenic potential in myeloproliferative diseases (MPDs). *Blood* 2002;100:ASH abstract 256.
- Furgerson JL, Vukelja SJ, Baker WJ, O'Rourke TJ. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. *Am J Hematol* 1996;51:137–40.
- Gaver RC, Deeb G, Pittman KA, Smyth RD. Disposition of anagrelide, an inhibitor of platelet aggregation. *Clin Pharm Ther* 1981;29:381–6.
- Gilbert H. Clinical status of anagrelide: a se-

Prof. Dr. med. Dr. med. habil. Petro E. Petrides, Schwerpunktpraxis für Hämatologie und Onkologie, Zweibrückenstr. 2, 80331 München, E-Mail: petrides@onkologiemuenchen.de

- lective agent for the control of thrombocythemia in myeloproliferative disorders. *Cancer Invest* 1991;9:343–4.
40. Gillespie E. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. *Biochem Pharmacol* 1988;37:2866–8.
 41. Gisslinger H. Einsatz von Anagrelid als Monotherapie und in Kombination mit Interferon-alpha oder Hydroxyurea. Ergebnisse der Studie AOP 02007. DGHO-Symposium München 2002.
 42. Golub R, Adams J, Dave S, Bennett CL. Cost effectiveness considerations in the treatment of essential thrombocythemia. *Sem Oncol* 2002;29(Suppl 10):28–32.
 43. Green A, Pearson T. Position paper on anagrelide. British Society of Hematology, February 2000.
 44. Hermann J, Fuchs D, Sauerbrey A, et al. Successful treatment of essential thrombocythemia with anagrelide in a child. *Med Ped Oncology* 1998;30:367–71.
 45. Herron KJ, Fleming JS, Solberg LA. Inhibition of megakaryocyte colonies in vitro by anagrelide. *Clin Res* 1986;34:459.
 46. Hong Y, Erusalimsky JD. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. *Platelets* 2003;13:381–6.
 47. James CW. Anagrelide induced cardiomyopathy. *Pharmacotherapy* 2000;20:1224–7.
 48. Kastner PR, Fleming JS, Gillespie E, et al. Inotropic and cardiovascular effects of anagrelide. *Proc FASEB* 1985;44:716.
 49. Kerns EH. Determination of anagrelide in plasma by capillary gas chromatography – mass spectrometry. *J Chromatography* 1987;416:357–64.
 50. Knutsen H, Hysing J. Anagrelide ved primær trombocytomi. *Tidsskr Nor Lægeforen* 2001;212:1478–82.
 51. Kornblihtt LI, Vassallu PS, Heller P, Molinas FC. Treatment of essential thrombocythemia with anagrelide: a ten year experience. *Medicina (B Aires)* 2002;62:231–6.
 52. Lackner H, Urban C, Beham-Schmid C, et al. Treatment of children with anagrelide for thrombocythemia. *J Ped Hematol/Oncol* 1998;20:469–73.
 53. Laguna MS, Kornblihtt LI, Marta RF, et al. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. *Clin Appl Thromb Hemost* 2000;6:157–61.
 54. Laguna MS, Kornblihtt LI, Marta RF, Molinas FC. Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide. *Medicina (B Aires)* 2000;60:448–52.
 55. Lane WJ, Hattori K, Dias S, Peerschke EI, et al. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. *Exp Hematol* 2001;29:1417–24.
 56. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of $600 \times 10^9/L$ be used as a diagnostic criterion in essential thrombocythemia? An analysis of the natural course including early stages. *Br J Hematol* 1998;100:15–23.
 57. Lev PR, Marta RF, Vassallu P, Molinas FC. Variation of PDGF, TGF- β and bFGF levels in essential thrombocythemia patients treated with anagrelide. *Am J Hematol* 2002;70:85–91.
 58. Mazur EM, Rosmarin AG, Sohl PA, et al. Analysis of the mechanism of anagrelide induced thrombocythemia in humans. *Blood* 1992;79:1931–7.
 59. Mazzuconi MG, DeSanctis V, Chistolini A, et al. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. *Hematologica* 1992;77:315–7.
 60. McCarty JM, Melone PM, Heisey C, Desypris EN. Differences in the species specific activity of anagrelide is mediated through the c-mpl receptor. *Blood* 2000;96:743a.
 61. McCune JS, Liles D, Luindley C. Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations. *Pharmacotherapy* 1997;17:822–6.
 62. McCune JS, Liles D, Luindley C. Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations – Author’s reply. *Pharmacotherapy* 1998;18:660–1.
 63. Mills AK, Taylor KM, Wright SJ, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythemia. *Aust N Z J Med* 1999;29:29–37.
 64. MRC Trial PT1. www.ctsuo.ox.ac.uk/projects/pt1/
 65. Nand S, et al. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. *Am J Hematol* 1996;52:42–6.
 66. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. *Am J Hematol* 2003;74:26–31.
 67. Nimer SD. Essential thrombocythemia: another “heterogeneous disease” better understood? *Blood* 1999;93:415–6.
 68. Oertel MD. Anagrelide, a selective thrombocytopenic agent. *Am J Health System Pharm* 1998;55:1979–86.
 69. Pescatore SL, Sindley C. Anagrelide: a novel agent for the treatment of myeloproliferative disorders. *Expert Opin Pharmacother* 2000;1:537–46.
 70. Pettitt RM, Petrides PE. Platelet reductive treatment with anagrelide in thrombocytic states: experiences in various centers and future directions. European working group on myeloproliferative disorders. Second Congress of the European Society of Hematology, Paris, May 1996.
 71. Pettitt R. Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations – A comment. *Pharmacotherapy* 1998;18:659.
 72. Pettitt RM, Silverstein MN, Petrone M. Anagrelide for control of thrombocythemia in polycythemia vera and other myeloproliferative disorders. *Sem Hematol* 1997;34:51–4.
 73. Petrides PE. Anagrelid: neues Therapeutikum bei primärer Thrombozytose. *Arzneimitteltherapie* 1993;11:71–3.
 74. Petrides PE. Agrelin® (Anagrelide) is an efficacious platelet reducing drug in patients with primary thrombocythemia. *Blood* 1994;84:S635a.
 75. Petrides PE, Beykirch MK, Hiller E, et al. Anagrelide, a novel specific inhibitory agent for patients with primary thrombocythemia. *Blut* 1994;111: abstract 443
 76. Petrides PE, Trapp OM, Beykirch MK. Anagrelide, a novel specific inhibitory agent for patients with primary thrombocythemia. *Onkologie* 1995;17(Suppl 2):111.
 77. Petrides PE. Treatment of essential thrombocythemia with Agrelin®: The German experience. *Br J Hematol* 1996;93(Suppl 2):237, abstract 892.
 78. Petrides PE, Trapp OM, Beykirch MK. Agrelin® (Anagrelide), a novel drug for the treatment of primary thrombocytoses (ET, PV and CML): Experience on 40 patients in Germany. *Ann Hematol* 1996;73(Suppl II):A97.
 79. Petrides PE, Trapp O, Beykirch MK. Anagrelide (Agrelin): Pharmakologisches Profil und klinische Anwendung. *Der Onkologe* 1997;3:298–302.
 80. Petrides PE, Trapp OM, Beykirch MK. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. *Blood* 1997;90(Suppl 1):ASH abstract 4009.
 81. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experience in 48 patients in Germany. *Eur J Hematol* 1998;61:71–6.
 82. Petrides PE, Beykirch MK. Long term follow up of patients with essential thrombocythemia under treatment with anagrelide. *Blood* 1999;94(Suppl 1):ASH abstract 4519.
 83. Petrides PE. Erhöhte Thrombozytenwerte: Was tun? *Berl Arzteblatt* 1998;11:588–90.
 84. Petrides PE, Beykirch MK. Efficacy of platelet reduction by anagrelide and safety of this drug in patients with primary thrombocythemia and other CMPDs: an overview of nine prospective non-randomized trials. *Hematol J* 2001;2(Suppl):16.
 85. Petrides PE. Chronisch myeloproliferative Erkrankungen. In: „Leukämien und myelodysplastische Syndrome“, Manual. Tumorzentrum München: Zuckschwerdt-Verlag, 2002:131–43.
 86. Petrides PE. Neue Erkenntnisse zur Pathogenese der Komplikationen chronisch myeloproliferativer Erkrankungen – Identifizierung von Risikofaktoren. DGHO-Symposium München 2002.
 87. Petrides PE. Primäre Thrombozythämie: Diagnose und Therapie. *Eingereicht*.
 88. Petrone ME, Wilson J, Pettitt RM, Silverstein MN. Anagrelide for treatment of thrombocythemia. *Br J Haematol* 1996;93(Suppl 2):237.
 89. Plapp F, Sinor L, Schmitz R, et al. Effect of anagrelide on platelet counts and size. *J Clin Pharmacol Ther* 1983;33:233, abstract C52.

90. Quaglinio D, DiLeonardo G, Stati M. Leukemic transformation in a case of thrombocyt haemia. Case report and review of the literature. *Acta Haematol* 2001;106:122–5.
91. Radin AI, Kim HK, Grant BW, et al. Phase II study of $\alpha 2$ interferon in the treatment of the chronic myeloproliferative disorders. *Cancer* 2003;98:100–9.
92. Rafil S, Lane W. In Response. *Exp Hematology* 2002;30:626–7.
93. Regev A, Stark P, Blickstein D, et al. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. *Am J Hematol* 1997;56:168–72.
94. Rhagawan M, Mazer MA, Brink DJ. Severe hypersensitivity pneumonitis associated with anagrelide. *Ann Pharmacother* 2003;37:1228–31.
95. Rosenbaum H, Bennett M, Braester A, et al. Toxicity of treatment with anagrelide for thrombocytosis in myeloproliferative disorders. *Blood* 2002;100:ASH abstract 3151.
96. Ruiz-Arguelles GJ, Ruiz-Delgado GJ, Ruiz-Reyes G, Chernoff SG. Anagrelide induced relapse of a hydroxyurea induced leg ulcer in a patient with primary thrombocythemia. *Mayo Clinic Proc* 1998;73:1125.
97. Sacchi S, Vinci G, Gugliotta L, et al. Diagnosis of essential thrombocythemia at platelets counts between 400 and 600 x 10⁹/L. *Haematologica* 2000;85:492–5.
98. Scherer S, Ferrari R, Rister M. Treatment of essential thrombocythemia in childhood. *Pediatr Hematol Oncol* 2003;20:361–5.
99. Schwonzon M, Spangenberg H, Spengler M. Hydroxyurea induced pneumonitis. *Med Klin* 2003;98:394–7.
100. Seiler S, Arnold AJ, Grove RI, et al. Effects of anagrelide on platelet cAMP levels, cAMP dependent protein kinase and thrombin induced calcium fluxes. *J Pharmacol Exp Therapeut* 1987;243:767–74.
101. Siegel F, Petrides PE. Long term analysis (up to 13,5 years) of patients with primary thrombocythemia treated with anagrelide. In Vorbereitung.
102. Silverstein MN, Petrone ME, Pettitt RM, Dement MP, et al. The safety profile of anagrelide for treatment of thrombocythemia. *Blood* 1996;88(Suppl 1):583a.
103. Silverstein MN, Pettitt RM, Solberg LA, Fleming JS, et al. Anagrelide: New drug for treating thrombocytosis. *New Engl J Med* 1988;318:1292–4.
104. Silverstein MN. Anagrelide in myeloproliferative diseases. In: Wasserman LR, Berk PD, Berlin NI (eds.). *Polycythemia vera and the myeloproliferative disorders*. Philadelphia: Saunders, 1995:329–36.
105. Silverstein MN, Tefferi A. Treatment of essential thrombocythemia with anagrelide. *Sem Hematol* 1999;36(Suppl 2):23–5.
106. Sironi M, Bertola G, Lodato A, et al. Transition of essential thrombocythemia to megakaryoblastic leukaemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea. *Acta Haematol* 2003;109:161–2.
107. Smith JB. Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase. *Thromb Res* 1992;28:477–85.
108. Solberg LA, Tefferi A, Oles KJ, Tarach JS, et al. The effects of anagrelide on human megakaryocytopoiesis. *Br J Haematol* 1997;99:174–80.
109. Spencer CM, Brodgen RN. Anagrelide. *Drugs* 1994;47:809–22.
110. Sterkers Y, Preudhomme C, Lai J-L, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. *Blood* 1998;91:616–22.
111. Steurer M, Gastl G, Jedrzejczak W, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Eingereicht.
112. Storen EC, Tefferi A. Long term use of anagrelide in young patients with essential thrombocythemia. *Blood* 2001;97:863–6.
113. Tang SS, Frojmovic MM. Inhibition of platelet function by antithrombotic agents which selectively inhibit low km cyclic AMP phosphodiesterase. *J Lab Clin Med* 1980;95:241–57.
114. Taylor R, Fleming S, Arnold J. The effect on platelets of a stable orally active imidazoquinazoline. *J Clin Pharmacol* 1984;24:423.
115. Tefferi A, Silverstein MN, Pettitt RM, Mesa RA, et al. Anagrelide as a new platelet lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. *Semin Thromb Hemost* 1997;23:379–83.
116. Thiele J, Kvasnicka HM, Schmitt-Gräff A. Anagrelid-induzierte Veränderungen der Megakaryopoese bei der Therapie thrombozythämischer chronischer myeloproliferativer Erkrankungen. *Pathologie* 2002;23:426–32.
117. Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, et al. Anagrelide induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies. *Haematologica* 2003;88:1130–8.
118. Tomer A, Stahl RL, Harker LA. Anagrelide normalizes platelet count in essential thrombocythemia by decreasing megakaryocyte hypermaturation. *Blood* 1991;78(Suppl 1):145a, ASH abstract 570.
119. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. *Blood* 2002;99:1602–9.
120. Trapp OM. Anagrelide: Ein neuer Wirkstoff zur Behandlung primärer Thrombozythämien [Dissertation]. München: Ludwig-Maximilians-Universität, 1999.
121. Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. *Blood Cells Mol Dis* 1998;24:9–13.
122. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, et al. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. *Cancer Chemother Pharmacol* 2003;52:229–34.
123. van Genderen PJ, Michiels JJ. Hydroxyurea in essential thrombocythemia. *N Engl J Med* 1995;333:801–3.
124. Voskaridou E, Terpos E, Komnina V, Eftyhiadis E, et al. Chronic myeloid leukemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide. *Br J Hematol* 2002;116:155–7.
125. Wahlin A, Golovleva I. Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Ph-negative essential thrombocythemia. *Eur J Hematol* 2003;70:240–1.
126. Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders. *Eur J Hematol* 1994;52:134–9.
127. Wirth K, Schoepf E, Mertelsmann R, et al. Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count. *Br J Hematol* 1998;138:533–5.
128. Yoon JM. Combination therapy for essential thrombocythemia. *Blood* 2002;100:ASH abstract 4923.
129. Yoon S-Y, Li C-Y, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. *Br J Hematol* 1999;106:682–8.